LONDON (Reuters) - A multidrug-resistant superbug infection that can cause life-threatening illness in people with cystic fibrosis (CF) has spread globally and is becoming increasingly virulent, British researchers said on Thursday.
In a study published in the journal Science, the researchers said the bug, a species of multidrug-resistant bacteria called Mycobacterium abscessus (M. abscessus), can cause severe pneumonia and is particularly dangerous for patients with CF and other lung diseases.
“The bug initially seems to have entered the patient population from the environment, but we think it has recently evolved to become capable of jumping from patient to patient, getting more virulent as it does so,” said Andres Floto, a Cambridge University professor who co-led the study.
Cystic fibrosis is a relatively rare genetic disorder that affects the respiratory, digestive and reproductive systems. It causes patients’ lungs to become clogged up with thick, sticky mucus and makes them vulnerable to respiratory infections.
In this study, researchers from Cambridge and the Wellcome Trust Sanger Institute sequenced the genomes of more than 1,000 samples of mycobacteria from 517 CF patients at specialist clinics in Europe, the United States and Australia.
They found that the majority of patients had picked up transmissible forms of M. abscessus that had spread globally.
Further analysis suggested the infection may be transmitted within hospitals via contaminated surfaces and through the air, the researchers said - presenting a serious challenge to infection control practices in hospitals.
Because the superbug has already become resistant to many antibiotics, it is also extremely difficult to treat successfully, Floto said. Patients infected with it need 18 months or more of treatment with a combination of powerful antibiotics, and fewer than one in three cases is cured.
Julian Parkhill of the Sanger Institute, who worked on this study, said that while its findings were alarming for CF patients, they did also provide a degree of hope.
“Now that we know the extent of the problem and are beginning to understand how the infection spreads, we can start to respond,” he said.
The sequencing data has thrown up potential new drug targets, he explained, and the researchers now plan to focus on seeking to develop new medicines to beat the bug.
(Reporting by Kate Kelland, editing by Mak Heinrich)
Support HuffPost
Our 2024 Coverage Needs You
Your Loyalty Means The World To Us
At HuffPost, we believe that everyone needs high-quality journalism, but we understand that not everyone can afford to pay for expensive news subscriptions. That is why we are committed to providing deeply reported, carefully fact-checked news that is freely accessible to everyone.
Whether you come to HuffPost for updates on the 2024 presidential race, hard-hitting investigations into critical issues facing our country today, or trending stories that make you laugh, we appreciate you. The truth is, news costs money to produce, and we are proud that we have never put our stories behind an expensive paywall.
Would you join us to help keep our stories free for all? Your contribution of as little as $2 will go a long way.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. Would you consider becoming a regular HuffPost contributor?
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. If circumstances have changed since you last contributed, we hope you’ll consider contributing to HuffPost once more.
Support HuffPostAlready contributed? Log in to hide these messages.